Catheter Precision secures up to $36.5M institutional financing; converts $9M liabilities into equity

Catheter Precision, Inc.

CEO David Jenkins exchanged royalty rights for ~9,490 shares of Series J Preferred Stock convertible into 6,083,005 common shares at $1.56, subject to stockholder approval.
ATM equity offering program terminated; no future equity lines or forward-priced agreements anticipated.
Short-term notes converted to long-term debt with maturities of 2-3 years.
Additional $9M in short and long-term liabilities converted into equity, strengthening balance sheet.
Up to $36.5M in institutional financing secured to expand market presence and advance growth initiatives.

item 1.01item 3.02item 5.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.